How to Buy Aprea Therapeutics Stock
Aprea Therapeutics Inc
Aprea Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways.
Aprea Therapeutics stock last closed at $1.55, up 5.1% from the previous day, and has decreased 69.82% in one year. It has overperformed other stocks in the Biotechnology industry by 0.07 percentage points. Aprea Therapeutics stock is currently +9.42% from its 52-week low of $1.41, and -73.81% from its 52-week high of $5.90.
There are currently 5.49M APRE shares outstanding. The market cap of APRE is $8.49M. In the last 24 hours, 9537 APRE shares were traded.
How to Buy Aprea Therapeutics Stock
Not sure how to invest in Aprea Therapeutics stock? Here's how.
- Decide where to buy Aprea Therapeutics stock: You need to choose a stock brokerage, but don't worry - we've sifted through dozens of online brokerages and apps to help you choose where to buy Aprea Therapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Fund your brokerage account: Select your method of payment and add your info.
- Evaluate Aprea Therapeutics stock: The Aprea Therapeutics ticker symbol is APRE. Is Aprea Therapeutics stock a good investment? Should you buy shares of APRE? How do APRE's underlying business fundamentals look? Do top analysts think Aprea Therapeutics is a good buy? Why has APRE's stock price moved recently? (Hint: Our stock research tools can help you decide if APRE is a good stock to buy).
- Make your APRE purchase: Decide if you will purchase APRE shares at the current market price or use a limit order to buy APRE shares at a particular price.
- Get notifications regarding your APRE investment: Create a watchlist to track your new investment in Aprea Therapeutics shares.
Step 1: Decide where to buy Aprea Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy APRE shares.
Our preferred brokerage: eToro
Based on our experience, eToro is the best brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world markets: From Technology to Real Estate, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro has a community with more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've selected your brokerage, you need to fill out some personal info so you are able to buy APRE stock today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to start your new brokerage account.
- Send your information by pressing the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you have created your account on the best stock market app for beginners, you can securely and quickly fund your account:
Watch the tutorial below if you need help transferring money into your investment account.
Step 4: Evaluate Aprea Therapeutics stock
Once you have figured out the best place to buy Aprea Therapeutics stock, it's crucial to evaluate their stock before you invest, so you can wrap your head around the risk and opportunity.
Aprea Therapeutics shares data
Fundamentals of APRE
WallStreetZen was built to help average investors perform more in-depth fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on APRE's stock page.
What is the fair value of APRE stock?
Analysts use many financial metrics, analyses, models, and charts to gauge APRE's intrinsic value.
Using relative valuations methods:
- APRE may be undervalued based on its P/B ratio of 0.44x, relative to Biotechnology industry P/B ratio of 4.16x
You can do more valuation research on APRE's stock here.
APRE Financial Health
Positive Financial Indicators:
- There are more short-term assets than short-term liabilities on the APRE balance sheet.
- APRE has cash burn of 13572196. It has sufficient cash and short-term investments to cover this for at least one year.
- APRE has $22.89M in cash and short term investments. This is enough to cover its annual cash burn of $13.57M.
- APRE has a low debt to equity ratio of 0.24.
- There are more short-term assets than long-term liabilities on the APRE balance sheet.
Negative Financial Indicators:
- APRE profit margin has gone up by 15.87 percentage points in the past year, but the company is still unprofitable.
- Total APRE debt is higher than 5 years ago, relative to shareholder equity.
Do analysts think it's a good time to buy Aprea Therapeutics stock
Out of 1 Wall Street analysts who monitor APRE, the consensus analyst rating on APRE is a Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
You can dive deeper into what analysts are forecasting on the Aprea Therapeutics stock forecast page.
Metrics for Advanced APRE Traders
APRE Earnings
Last year, APRE revenue was $1.50M. Over the last one years, APRE's revenue has increased by 157.63% per year. This was faster than the Biotechnology industry average of 44.4%.
Dive into APRE's earnings and revenue performance here.
Are APRE insiders buying or selling the stock?
In the past 12 months, executives and large shareholders at APRE have bought more shares than they have sold.
Oren Gilad, PresidentCEO of APRE, was the latest APRE insider to buy. They bought $5,615.61 worth of APRE stock on Apr 3, 2025.
Learn more about who owns APRE stock here.
Can I get consistent income from APRE stock?
No, Aprea Therapeutics doesn't provide an income stream by paying out dividends.
APRE Social Trading Data
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your APRE purchase
You have two main order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are usually sufficient. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a given dollar amount limit, place a limit order.
Press the Open button and your broker will place the order.
If you require more help with investing in stocks on eToro, click the how to video below:
Step 6: Get notifications regarding your APRE investment
Now that you own some APRE shares, you'll want to stay up-to-date on your investment.
Make a watchlist to track your APRE stock.
APRE Feed
How to Buy Stock in Aprea Therapeutics
To summarize, here are the 6 steps to buy stock in Aprea Therapeutics:
- Decide where to buy Aprea Therapeutics stock
- Open your brokerage account
- Fund your brokerage account
- Evaluate Aprea Therapeutics stock
- Make your APRE purchase
- Get notifications regarding your APRE investment
If you need a brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to get updates on your new investment in Aprea Therapeutics, create a watchlist on WallStreetZen today.
Other "How To" Guides You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.